帕瑞昔布钠对肝癌患者七氟醚麻醉苏醒期躁动的影响

Effects of parecoxib sodium on emergence agitation for patients with liver cancer under sevoflurane anesthesia

目的探讨帕瑞昔布钠对肝癌患者七氟醚麻醉苏醒期躁动的影响。方法选取七氟醚麻醉下行肝癌手术患者共76例,其中38例为帕瑞昔布钠组(P组),余38例为对照组(C组)。P组和C组在手术结束前30 min分别静脉推注帕瑞昔布钠40 mg、舒芬太尼10μg进行治疗,在拔管后15 min、30 min进行生命体征比较及在拔管后15 min记录疼痛VAS评分和躁动RS评分,同时观察患者有无恶心呕吐、嗜睡、呼吸抑制等不良反应。结果两组患者的年龄、体重、身高、手术时间、切口长度、VAS评分等一般资料差异均无统计学意义(P>0.05);P组的RS评分、恶心呕吐、嗜睡的发生率明显低于C组,差异有统计学意义(P<0.05);两组患者苏醒期间生命体征稳定,无呼吸抑制,各引流管引流通畅,无受压扭曲。结论帕瑞昔布钠可有效减少肝癌患者七氟醚麻醉苏醒期患者的躁动。

Objective To explore the effects of parecoxib sodium on emergence agitation for patients with liver cancer under sevoflurane anesthesia. Methods A total of 76 patients received liver cancer surgery under sevoflurane anesthesia. Among them, 38 patients were assigned to the parecoxib group （P group）, and the other 38 patients were assigned to the control group （C group）. P group and C group were given intravenous injection of 40 mg of parecoxib and 10μg of sevoflurane respectively 30 rain before the completion of the surgery. The vital signs were observed 15 min and 30 min after the extubation, pain VAS score and agitation RS score were calculated 15 min after the extubation, and at the same time, patients＇ adverse effects such as nausea and vomiting, drowsiness and respiratory depression were observed. Results General data such as age, weight, height, surgery time, incision length and VAS scores between the two groups of patients were not statistically significant（P〉0.05）; RS scores, and incidence rate of nausea, vomiting, and drowsiness in P group were significantly lower than those in C group, and the differences were statistically significant （P〈0.05）; during emergence, the two groups of patients showed stable vital signs without respiratory depression. All drainage tubes were unobstructed without being compressed or distorted. Conclusion Parecoxib is effective in reducing the agitation of patients with liver cancer during the emergence of sevoflurane anesthesia.